Labcorp

Labcorp Expands MRD Testing Portfolio and Reaffirms Dividend Amidst Oncology Innovation Story

徕博科

Labcorp to announce Q4 2025 financial results on February 17.

Labcorp's 15min chart shows Bollinger Bands Narrowing, Bearish Marubozu.

Labcorp's 15min chart triggered KDJ Death Cross, Bearish Marubozu Signal.

Labcorp Holdings Announces $0.72 Quarterly Dividend, Payable March 12.

Catalyst<ul> <li>Most analysts rate LH Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Fund flow analysis indicates net outflows across all order sizes, signaling short-term institutional caution.</li></ul>

Key Factors

Labcorp will announce Q4 2025 financial results on February 17, 2026, with a conference call and webcast scheduled for 9 a.m. ET.Labcorp declared a quarterly dividend of $0.72 per share, payable on March 12, 2026, to shareholders of record as of February 27, 2026.Labcorp expanded its molecular residual disease testing to include earlier detection of recurrence for stage I-III breast, stage I-IIIA non-small cell lung, and stage III colon cancers.

LH News